Aspirin-Containing Antiplatelet Therapy and In-Hospital Gout Flares in Acute Ischemic Stroke Patients with Gout and Hyperuricemia: A Retrospective New-User Cohort Study
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Antiplatelet selection is challenging in patients with acute ischemic stroke (AIS), gout, and hyperuricemia. We compared the risk of in-hospital gout flares between aspirin-containing regimens and clopidogrel monotherapy, and examined subsequent aspirin discontinuation during dual antiplatelet therapy (DAPT).
Methods
A retrospective new-user cohort study was conducted based on electronic medical records (2019–2025). Patients were categorized into aspirin-containing therapy (aspirin monotherapy or DAPT with aspirin plus clopidogrel) and clopidogrel monotherapy groups. The primary analysis used IPTW-adjusted logistic regression. Interaction tests assessed effect modification and a Sankey diagram visualized DAPT treatment transition.
Results
Among 105,890 screened patients, 457 were enrolled (234 aspirin-containing therapy, 223 clopidogrel monotherapy). In-hospital gout flares occurred in 187 (40.9%). Aspirin-containing regimens were associated with a higher flare risk (OR = 1.57, 95% CI 1.07 – 2.31, P = 0.022). Results were consistent in sensitivity analyses. Higher SUA (OR 1.20 per 1-mg/dL increase, 95% CI 1.03–1.40; P = 0.023) and baseline mRS ≥3 (OR 2.13, 95% CI 1.42–3.20; P < 0.001) were independently associated with in-hospital gout flares. No significant interactions were observed between antiplatelet regimens and SUA, mRS or urate-lowering therapy (ULT). Among DAPT recipients, aspirin discontinuation in patients with gout flares was 65.2%, 66.7%, and 56.0% in 2019–2021, 2022–2023, and 2024–2025, respectively, versus 47.8%, 28.6%, and 11.9% in those without flares.
Conclusions
In AIS patients with gout and hyperuricemia, initiating aspirin-containing regimens was associated with a higher risk of in-hospital gout flares compared with clopidogrel monotherapy. Gout flares during DAPT were accompanied by frequent aspirin discontinuation, which may limit completion of guideline-recommended DAPT. Prospective studies are needed.
